Speaker
Gayatri Devi
Appearances over time
1 episodes
Episodes
1
Podcasts
Quotes & moments
Amyloid deposition can begin two to three decades before the onset of clinical cognitive symptoms.
About 25% of community-dwelling people in their seventies have amyloid in their brains without any symptoms of dementia.
By age 90, approximately 44% of community-dwelling people have brain amyloid without dementia symptoms, undermining blood-test specificity.
Gayatri Devi's slow-titration protocol for APOE4 carriers on anti-amyloid monoclonal antibodies yields only a 4% rate of ARIA, far below standard protocols.
Autopsy studies show that between 98% and 99% of Alzheimer's patients have some form of concomitant primary brain pathology, most commonly vascular disease.
About 40% of Alzheimer's patients eventually develop some level of Lewy body pathology, illustrating significant dementia overlap.
Anti-amyloid therapies like lecanemab and donanemab show only 0.3–0.4 point improvements on the 18-point CDR Sum of Boxes scale, a modest but potentially meaningful shift.
Approximately 30% of patients enrolled in Alzheimer's drug trials did not actually have Alzheimer's by pathology, having been misdiagnosed clinically.
Carrying two copies of the APOE4 allele increases Alzheimer's risk by approximately 60% compared to the APOE3/3 wild type, analogous to carrying the BRCA gene for breast cancer.
Aducanumab carried a greater than 40% incidence of abnormal brain bleeding and swelling (ARIA), driving Gayatri Devi to develop her slow-titration protocol.
Despite years of liberal monoclonal antibody use, Gayatri Devi has seen only one case of symptomatic ARIA; all other cases were detected only on MRI.
Studies of identical twins raised in the same environment show one twin may not develop Alzheimer's for 10–15 years after the other, highlighting the role of epigenetics and individual brain differences.
Lecanemab and donanemab each cost approximately $26,000 per year for the drug alone, with additional administration fees ranging from $400 to $10,000 per infusion.
Gayatri Devi has used transcranial magnetic stimulation (TMS) off-label for treating dementia patients since 2008, targeting specific brain circuits to maintain function.
Menopausal women have estrogen levels below 30–35 pg/dL; a 21-year-old patient of Gayatri Devi with severe brain fog had an estrogen level of just 22 pg/dL.
The classic amyloid-first model of Alzheimer's pathology is being overturned. Neuroimmunological changes may precede amyloid deposition by years or decades, opening a window for anti-inflammatory intervention as early as your 30s and 40s to prevent the entire cascade from triggering.
One patient cleared her brain amyloid and then subsequently showed no tau on a tau PET scan — a response Gayatri Devi describes as so remarkable she 'refuses to believe' the pathology is gone. Another patient, an identical twin of a facility-dwelling Alzheimer's patient, did so well on monoclonal therapy despite having a mechanical heart valve and being on Coumadin.
A punch biopsy of the skin is actually a biopsy of cutaneous small nerves, which carry alpha-synuclein along their length. Biopsies at multiple levels — neck, knee, lower extremity — reveal how widely spread the synuclein pathology is, distinguishing Lewy body disease from other motor disorders without a lumbar puncture.
Lewy body dementia and Parkinson's disease share identical alpha-synuclein pathology; the only real difference is timing. But clinically misclassifying Lewy body as Parkinson's leads to dopaminergic drugs that worsen confusion and can trigger psychosis. The pill-rolling tremor of Parkinson's is a key distinguishing feature Gayatri Devi has never seen in Lewy body.
Aducanumab was approved in 2021 against its FDA advisory board's recommendation because clearing amyloid didn't translate to clear clinical benefit in the trials. Gayatri Devi prescribed it anyway, applying a simple personal test: would she want it herself if she had Alzheimer's? Her answer was yes.
Before monoclonal antibodies, Gayatri Devi was already deploying a complex toolkit: cholinesterase inhibitors, memantine, valacyclovir, WATCHMAN procedures to get patients off blood thinners, and transcranial magnetic stimulation since 2008. Today these tools remain core elements of her multimodal approach alongside anti-amyloid therapies.
For decades, Gayatri Devi assumed any Alzheimer's patient who improved had been misdiagnosed. Only when spinal tap biomarkers confirmed true Alzheimer's pathology in patients who then got better did she allow herself to believe improvement was real. It took five to eight more years before she truly believed it — and now she does.
Standard cognitive tests like the MoCA or MMSE are nearly useless for highly intelligent patients — many score a perfect 30 well into their condition. Real evaluation requires multi-hour neuropsychological testing, brain blood flow measurement, EEG, specialized MRI, and often amyloid and tau PET scans.
Menopause-related cognitive impairment can be treated with estrogen replacement (preferably transdermal to reduce stroke risk), targeted brain exercises using constraint-induced principles, cholinesterase inhibitors, and TMS. A small double-blind trial of donepezil in menopausal women showed a trend toward cognitive improvement.
Forgetting names is neurologically normal and almost never a sign of Alzheimer's. The real red flag is difficulty recalling common nouns — struggling to find the word 'chair' or 'book' — because that kind of semantic memory is housed in a different, more diagnostically significant brain region.
The Women's Health Initiative in 2002 triggered a mass withdrawal of hormone replacement therapy from an entire generation of women. Those women, now in their 70s, may be experiencing higher rates of Alzheimer's disease as a direct consequence — a cohort-level outcome that Peter Attia and Gayatri Devi describe as a preventable tragedy.
Blood-based Alzheimer's biomarkers are validated against amyloid PET scans — but 25–44% of people over 70 have amyloid in their brains without any dementia. Diagnosing Alzheimer's from a blood test alone risks creating a massive population of 'patients in waiting' who may never develop disease.
The next decade in Alzheimer's care will likely be defined by AI monitoring of subtle changes in cognitive patterns for early detection, targeted anti-inflammatory and anti-pathology drug cocktails for high-risk individuals, and neuromodulation techniques as a complement to pharmacotherapy. Gayatri Devi's vision mirrors the cancer oncology shift toward mutation-specific, subtype-specific treatment.
Estrogen loss at menopause drives measurable cognitive decline — including memory problems, word-finding difficulties, and executive dysfunction — that is clinically indistinguishable from early Alzheimer's disease. Gayatri Devi has treated multiple women who were misdiagnosed with Alzheimer's when they actually had reversible menopause-related cognitive impairment.
Alzheimer's and other dementias exist on a wide spectrum — from barely detectable impairment to rapid severe decline — and the disease's presentation depends heavily on the individual's brain reserve, comorbidities, and the area of brain affected. Treating it as an all-or-nothing condition misses most of the clinical picture.
Analysis
What they talk about
- Health & Fitness 87%
- Science 7%
- Technology 6%
